BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 28243849)

  • 1. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloma bone disease: pathogenesis and treatment.
    O'Donnell EK; Raje NS
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):285-295. PubMed ID: 28591104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
    Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
    Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloma and Bone Disease.
    Panaroni C; Yee AJ; Raje NS
    Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; MaƂecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the biology and treatment of bone disease in multiple myeloma.
    Raje N; Roodman GD
    Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone disease in multiple myeloma].
    Irisawa H
    Nihon Rinsho; 2015 Jan; 73(1):42-6. PubMed ID: 25626302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone markers in multiple myeloma.
    Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
    Yen CH; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.